{"id":2453,"date":"2017-02-01T12:05:00","date_gmt":"2017-02-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/quo-vadis-fda-in-der-aera-trump"},"modified":"2017-02-01T12:05:00","modified_gmt":"2017-02-01T11:05:00","slug":"quo-vadis-fda-in-der-aera-trump","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/quo-vadis-fda-in-der-aera-trump","title":{"rendered":"Quo vadis FDA in der \u00c4ra Trump?"},"content":{"rendered":"<p>Der gerade erst in sein Amt eingef\u00fchrte neue Pr\u00e4sident der USA, Donald Trump, hat am 31. Januar 2017 seine Visionen zur zuk\u00fcnftigen Arzneimittelpolitik in den USA verk\u00fcndet. Eingeladen ins Wei\u00dfe Haus hatte er hierzu f\u00fchrende Vertreter pharmazeutischer Unternehmer (pU) von AMGEN, Celgene, Eli Lilly, Johnson &#038; Johnson, Merck und Novartis sowie den Leiter des Branchenverbands [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Der gerade erst in sein Amt eingef\u00fchrte neue Pr\u00e4sident der USA, Donald Trump, hat am 31. Januar 2017 seine Visionen zur zuk\u00fcnftigen Arzneimittelpolitik in den USA verk\u00fcndet. Eingeladen ins Wei\u00dfe Haus hatte er hierzu f\u00fchrende Vertreter pharmazeutischer Unternehmer (pU) von AMGEN, Celgene, Eli Lilly, Johnson &#038; Johnson, Merck und Novartis sowie den Leiter des Branchenverbands [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[255,3834,3833,257,843,846,4832],"class_list":["post-2453","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-arzneimittel","tag-fda","tag-food-and-drug-administration","tag-medikamente","tag-pharmaindustrie","tag-pharmazeutische-unternehmer","tag-trump"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2453"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2453\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}